Secondary endpoint: Trilineage hematological response rate (CR and PR) at 12 months

One secondary endpoint of the study is the (trilineage) hematologic response rate (CR + PR) at 12 months. The response assessment will be calculated as defined by the response criteria according to the protocol. Additionally, the investigator will classify hematologic response. Both assessments will be evaluated descriptively, but the calculated assessment will be prevailing for hypothesis testing.

Evaluation of all secondary endpoints will be based on the FAS, if not stated otherwise.

Proportions of hematological response will be estimated 12 months after therapy start for each group and study arm. Withdrawals and dropouts in the preceding period since last response assessment will be listed in the descriptive table as “missing response”.

A comparison between treatment arms (Placebo and Eltrombopag) will be performed after 3, 12 and 18 months after therapy start. At 12 and 18 months treatment groups (A1, A2, B, C) will be compared pairwise: For the comparison withdrawals, dropouts, and missing assessments will be counted in the category “no response”.

The null hypothesis that the OR is 1 will be tested by Fisher’s exact test and will be rejected if the p-value is below 0.05. A lower 95% confidence limit for the OR will be provided.

Confidence limits according to Agresti and Coull for the proportions of response will be computed.

Results:

Response assessment			**NA (not applicable)**		**CR (complete remission)**		**PR (partial remission)**		**NR (no response)**		**Yes (response = CR + PR))**	
Visit	**Parameter**	**Arm**	**N**	**%**	**N**	**%**	**N**	**%**	**N**	**%**	**N**	**%**
After 12 months	Investigator assessment	A	4	10.5	11	28.9	14	36.8	9	23.7		
		B	1	50.0	1	50.0						
		C			9	34.6	14	53.8	3	11.5		
		D	7	77.8			2	22.2				
		Other	10	100.0								
		Total	22	25.9	21	24.7	30	35.3	12	14.1		
	Calculated assessment	A	6	15.8	10	26.3	13	34.2	9	23.7		
		B	1	50.0	1	50.0						
		C	1	3.8	8	30.8	14	53.8	3	11.5		
		D	7	77.8			2	22.2				
		Other	10	100.0								
		Total	25	29.4	19	22.4	29	34.1	12	14.1		
	CR or PR according investigator assessment	A									25	65.8
		B									1	50.0
		C									23	88.5
		D									2	22.2
		Other										
		Total									51	60.0